Adaptimmune Therapeutics Plc (ADAP) — Cash Flow-to-Debt Ratio
Adaptimmune Therapeutics Plc (ADAP) has a Cash Flow-to-Debt Ratio of -0.17x as of June 2025, meaning its operating cash flow of $-34.78 Million could theoretically repay 0% of its total liabilities ($201.59 Million) in one year. Check Adaptimmune Therapeutics Plc cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Adaptimmune Therapeutics Plc Cash Flow-to-Debt Ratio (2012–2024)
Historical debt coverage capacity for Adaptimmune Therapeutics Plc across 13 annual periods. Also explore Adaptimmune Therapeutics Plc (ADAP) total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Adaptimmune Therapeutics Plc (2012–2024)
Year-by-year debt coverage analysis for Adaptimmune Therapeutics Plc. For market capitalisation and broader financial context, see Adaptimmune Therapeutics Plc (ADAP) total market value.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.31x | $-73.21 Million | $234.11 Million | ▲ +46.0% |
| 2023 | -0.58x | $-140.88 Million | $243.10 Million | ▼ -1.0% |
| 2022 | -0.57x | $-141.77 Million | $247.04 Million | ▼ -1509.9% |
| 2021 | 0.04x | $10.73 Million | $263.58 Million | ▲ +108.3% |
| 2020 | -0.49x | $-53.59 Million | $109.92 Million | ▲ +74.9% |
| 2019 | -1.94x | $-112.51 Million | $57.91 Million | ▲ +44.4% |
| 2018 | -3.50x | $-104.39 Million | $29.85 Million | ▼ -403.2% |
| 2017 | -0.69x | $-54.31 Million | $78.16 Million | ▲ +1.4% |
| 2016 | -0.70x | $-48.17 Million | $68.37 Million | ▲ +11.6% |
| 2015 | -0.80x | $-32.74 Million | $41.07 Million | ▼ 0.0% |
| 2014 | -0.80x | $-32.74 Million | $41.07 Million | ▼ -213.7% |
| 2013 | 0.70x | $37.23 Million | $53.11 Million | ▲ +135.8% |
| 2012 | -1.96x | $-7.77 Million | $3.97 Million | — |